Skip to main content
SpringerLink
Log in

Prostate Cancer

  • Chapter
Geriatric Medicine

  • 231 Accesses

Abstract

Cancer is a significant problem in an elderly population. Among males no cancer is more prevalent than prostate cancer. In 1995 prostate cancer was the most commonly diagnosed cancer in the United States with an estimated 240,000 new cases.1 Prostate cancer was second only to lung cancer as a cause of cancer death in men in 1995, with an estimated 40,400 deaths. Cancer is second only to heart disease as a cause of death in adults, and prostate cancer accounts for one fifth of the cancer deaths in men over the age of 75. One of every eight men in the 60- to 79-year age group will be diagnosed with prostate cancer, as compared with one in 15 women of the same age who will be diagnosed with breast cancer. Although many patients with prostate cancer do not die as a consequence of their malignancy, a significant number require treatment of symptoms associated with the disease such as pain, bleeding, and urinary obstruction. Thus, prostate cancer is a major cause of mortality, morbidity, and health care expenditure in the elderly male population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995; 45: 8–30.

    Article  PubMed  CAS  Google Scholar 

  2. Data from the Surveillance, Epidemiology, and End Results (SEER) Program Staff. Section III: Incidence. In: Cancer Statistics Review 1973–1986 Bethesda, MD: NIH; 1989:1IL45.

    Google Scholar 

  3. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate. 1990; 16: 39–48.

    Article  PubMed  CAS  Google Scholar 

  4. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol. 1993; 150: 797–802.

    PubMed  CAS  Google Scholar 

  5. Spitz MR, Currier RD, Fueger JJ, et al. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991; 146: 1305–1307.

    PubMed  CAS  Google Scholar 

  6. Tulinius H, Egilsson V, Olafsdottir GH, et al. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Br Med J. 1992; 305: 855857.

    Google Scholar 

  7. Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer. 1974; 34: 1102–1107.

    Article  PubMed  CAS  Google Scholar 

  8. Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Human Genet. 1993; 52: 711–717.

    CAS  Google Scholar 

  9. Collins VP, Kunimi K, Bergerheim U, et al. Molecular genetics and human prostatic carcinoma. Acta Oncol 1991; 30: 181–185.

    Article  PubMed  CAS  Google Scholar 

  10. Sakr WA, Macoska JA, Benson P, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res. 1994;54:3273–3277

    Google Scholar 

  11. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793–803.

    PubMed  CAS  Google Scholar 

  12. Waterhouse J, Muir C, Shanmugaratnam K, et al. Cancer incidence in five continents. In: Anonymous Cancer Incidence. Lyon, France: International Agency for Research in Cancer; 1982.

    Google Scholar 

  13. Dunn JE. Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res. 1975; 35: 3240–3245.

    PubMed  CAS  Google Scholar 

  14. Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles county. Br J Cancer. 1991; 63: 963966.

    Google Scholar 

  15. Meikle AW, Smith JA, Jr. Epidemiology of prostate cancer. Urology Clin North Am. 1990; 17: 709–718.

    CAS  Google Scholar 

  16. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993; 85: 1571–1579.

    Article  PubMed  CAS  Google Scholar 

  17. Hayes RB, Bogdanovicz JF, Schroeder FH, et al. Serum retinol and prostate cancer. Cancer. 1988; 62: 2021–2026.

    Article  PubMed  CAS  Google Scholar 

  18. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990; 10: 1307–1312.

    PubMed  CAS  Google Scholar 

  19. Bennett CL, Greenfield S, Aronow H, et al. Patterns of care related to age of men with prostate cancer. Cancer. 1991; 67: 2633–2641.

    Article  PubMed  CAS  Google Scholar 

  20. Cook GB, Watson FR. A comparison by age of death rates due to prostate cancer alone. J Urol. 1968; 100: 669671

    Google Scholar 

  21. Smedley HM, Sinnott M, Freedman LS, et al. Age and survival in prostatic carcinoma. Br J Urol. 1983; 55: 529533.

    Google Scholar 

  22. Ishigawa S, Soloway MS, Van Der Zwaag R, et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol. 1988; 141: 1139–1142.

    Google Scholar 

  23. Chodak GW, Vogelzang NJ, Caplan RJ, et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. DAMA. 1991; 265: 618–621.

    CAS  Google Scholar 

  24. Johansson JE, Andersson SO, Holmberg L, et al. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol. 1991; 146: 1327 1333.

    Google Scholar 

  25. Emrich LJ, Priore RL, Murphy GP, et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985; 45: 5173–5179.

    PubMed  CAS  Google Scholar 

  26. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993; 119: 914–923.

    PubMed  CAS  Google Scholar 

  27. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. DAMA. 1995; 273: 289–294.

    CAS  Google Scholar 

  28. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909–916.

    Article  PubMed  CAS  Google Scholar 

  29. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991; 145: 313–318.

    PubMed  CAS  Google Scholar 

  30. Whitmore WF. Hormone therapy in prostatic cancer. Am J Med. 1956; 21: 697–713.

    Article  PubMed  Google Scholar 

  31. Jewett HJ. The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am. 1975; 2: 105–124.

    PubMed  CAS  Google Scholar 

  32. Montie JE. 1992 staging system for prostate cancer. Semin Urol. 1993; 11: 10–13.

    PubMed  CAS  Google Scholar 

  33. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50: 125.

    PubMed  CAS  Google Scholar 

  34. Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer. 1992; 70: 161–168.

    Article  PubMed  CAS  Google Scholar 

  35. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150: 110–114X.

    PubMed  CAS  Google Scholar 

  36. McGowan DG, Bain GO, Hanson J. Evaluation of histological grading (Gleason) in carcinoma of the prostate: adverse influence of highest grade. Prostate. 1983; 4: 11 1118.

    Google Scholar 

  37. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994; 330: 242–248.

    Article  PubMed  CAS  Google Scholar 

  38. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994; 331: 996–1004.

    Article  PubMed  CAS  Google Scholar 

  39. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Patient reported complications and follow up treatment after radical prostatectomy: The National Medicare Experience: 19881990. Urology. 1993; 42: 622–629.

    Article  PubMed  Google Scholar 

  40. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J UroL 1981; 128: 502–503.

    Google Scholar 

  41. Byar DP, Corle DK. VACURG randomized trial of radical prostatectomy for stages I and II prostate cancer. Urology Suppl. 1981; 17: 7–11.

    CAS  Google Scholar 

  42. Madsen PO, Graversen PH, Gasser TC, et al. Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up. Scand J Urol Nephrol Suppl. 1988; 110: 95–100.

    PubMed  CAS  Google Scholar 

  43. Epstein JI, Paull G, Eggleston JC, et al. Prognosis of untreated stage Al prostatic carcinoma: a study of 94 cases with extended followup. J UroL 1986; 136: 837–839.

    PubMed  CAS  Google Scholar 

  44. George NJR. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. 1988; 1: 494–497.

    Article  PubMed  CAS  Google Scholar 

  45. Adolfsson J, Ronstrom L, Carstensen J, et al. The natural course of low grade, non-metastatic prostatic carcinoma. Br J Urol. 1990; 65: 611–614.

    Article  PubMed  CAS  Google Scholar 

  46. Zhang G, Wasserman NF, Sidi AA, et al. Long-term follow-up results after expectant management of stage Al prostatic cancer. J Urol. 1991; 146: 99–103.

    PubMed  CAS  Google Scholar 

  47. Whitmore WF Jr, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer. 1991; 67: 1091–1096.

    Article  PubMed  Google Scholar 

  48. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol. 1992; 69: 183–187.

    Article  PubMed  CAS  Google Scholar 

  49. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol. 1994; 152: 1753 1756.

    Google Scholar 

  50. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1–2NOMO prostatic adenocarcinoma: long term results. J Urol. 1990; 144: 1180–1184.

    PubMed  CAS  Google Scholar 

  51. Hanks GE. External beam radiation treatment for prostate cancer: still the gold standard. Oncology. 1992; 6: 7994.

    Google Scholar 

  52. Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993; 72: 1291–1299.

    Article  PubMed  CAS  Google Scholar 

  53. Schroeder FH, Belt E. Carcinoma of the prostate: a study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol. 1974; 114: 257260.

    Google Scholar 

  54. Zagars GK, von Eschenback AC, Johnson DE, et al. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer. 1987; 60: 1489–1499.

    Article  PubMed  CAS  Google Scholar 

  55. Gee WF, Cole JR. Symptomatic stage C carcinoma of the prostate. Traditional therapy. Urology. 1980; 15: 335–337.

    Article  PubMed  CAS  Google Scholar 

  56. Zincke H, Utz DC, Taylor WF. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J UroL 1985; 135: 1199–1205.

    Google Scholar 

  57. Paulson DF, Hodge GB Jr, Hinshaw W. Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J Urol. 1984; 131: 901–902.

    PubMed  CAS  Google Scholar 

  58. Gibbons RP, Cole BS, Richardson RG, et al. Adjuvant radiotherapy following radical prostatectomy: results and complications. J UroL 1986; 135: 65–68.

    PubMed  CAS  Google Scholar 

  59. Kramer SA, Cline WA, Farnham R, et al. Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol. 1981; 125: 817–819.

    PubMed  CAS  Google Scholar 

  60. Steinberg GD, Epstein JI, Piantadosi S, et al. Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974 to 1987. J Urol. 1990; 144: 1425 1431.

    Google Scholar 

  61. Cheng CW, Bergstralh EJ, Zincke H. Stage Dl prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer. 1993; 71: 996–1004.

    Article  PubMed  CAS  Google Scholar 

  62. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23: 211–222.

    Article  PubMed  CAS  Google Scholar 

  63. Huggins C, Hodges CV. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293–297.

    CAS  Google Scholar 

  64. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984; 311: 1281–1286.

    Google Scholar 

  65. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic cancer. Urology. 1989; 33: 45–52.

    Article  PubMed  CAS  Google Scholar 

  66. De Voogt HJ, Smith PH, Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European organization for research on treatment of cancer trials 30761 and 30762. J Urol. 1986; 135: 303–307.

    PubMed  Google Scholar 

  67. Lin BJ, Chen KK, Chen MT, et al. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology. 1994; 43: 834–837.

    Article  PubMed  CAS  Google Scholar 

  68. Ahmann FR, Citrin DL, De Haan HA, et al. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol. 1987; 5: 912–917.

    PubMed  CAS  Google Scholar 

  69. Bennett CL, McLeod DG, Hillner BE. Estimating the cost-effectiveness of total androgen blockade (TAB) for stage D-2 prostate cancer (meeting abstract) Proc Ann Meet Am Soc Clin Oncol. 1994;13

    Google Scholar 

  70. Warner B, Worgul TJ, Drago J, et al. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. Clin Invest. 1983; 71: 1842 1853.

    Google Scholar 

  71. Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol. 1990; 144: 934–941.

    PubMed  CAS  Google Scholar 

  72. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983; 4: 579594.

    Google Scholar 

  73. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321: 419–424.

    Article  PubMed  CAS  Google Scholar 

  74. Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 1991; 146: 1321–1326.

    PubMed  CAS  Google Scholar 

  75. Nicol DL, Heathcote PS, Kateley GD, et al. Advanced prostate cancer. The role of high priced hormone therapy. Med J Aust. 1993; 159: 16–19.

    PubMed  CAS  Google Scholar 

  76. Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993;118:860–864

    Google Scholar 

  77. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993; 149: 607–609.

    PubMed  CAS  Google Scholar 

  78. Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993; 150: 908913.

    Google Scholar 

  79. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994; 43: 408–410.

    Article  PubMed  CAS  Google Scholar 

  80. Smith DC, Bahnson RR, Trump DL. Secondary hormonal manipulation (prostate cancer). In: Vogelzang NJ, Scardino PT, Shipley WU, et al., eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams & Wilkins; 1995.

    Google Scholar 

  81. Loprinzi CL, Ellison NM, Goldberg RM, et al. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Semin Oncol. 1990; 17: 8–12.

    PubMed  CAS  Google Scholar 

  82. Eisenberger M. How effective is cytotoxic chemotherapy for disseminated prostatic cancer. Oncology. 1987; 1: 59.

    PubMed  CAS  Google Scholar 

  83. Eisenberger MA, Simon R, O’Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma.J Clin Oncol. 1985;3:827–841

    Google Scholar 

  84. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71: 1098–1109.

    Article  PubMed  CAS  Google Scholar 

  85. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol. 1985;3:1013-1021

    Google Scholar 

  86. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer J Clin Oncol. 1992;10:1754–1761

    Google Scholar 

  87. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992; 147: 931–934.

    PubMed  CAS  Google Scholar 

  88. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate J Clin Oncol. 1994;12:2005–2012

    Google Scholar 

  89. Myers CE, Cooper MR, La Rocca R, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol. 1992;10:881–889

    Google Scholar 

  90. Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst. 1993; 85: 611–621.

    Article  PubMed  CAS  Google Scholar 

  91. Trump D, Smith DC, Adedoyin A, et al. All-trans retinoic acid (ATRA) in hormone refractory prostate Cancer (HRPC): ineffectiveness due to failure of drug delivery Proc Am Soc Clin Oncol. 1994;13:241

    Google Scholar 

  92. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994; 151: 622–628.

    PubMed  CAS  Google Scholar 

  93. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132: 1952–1960.

    Article  PubMed  CAS  Google Scholar 

  94. Flynn DF, Shipley WU. Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am. 1991;18:145–152

    Google Scholar 

  95. Vecht CJ, Haaxma-Reiche H, van Putten WLJ, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression Neurology. 1989;39:1255–1257

    Google Scholar 

  96. Smith EM, Hampel N, Ruff RL, et al. Spinal cord compression secondary to prostate carcinoma: treatment and prognosis. J Urol. 1993; 149: 330–333.

    PubMed  CAS  Google Scholar 

  97. Shoskes DA, Perrin RG. The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. J Urol. 1989; 142: 337–339.

    Google Scholar 

  98. Dijstra S, Wiggers T, van Geel BN, et al. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. Eur J Surg. 1994; 160: 535–542.

    PubMed  CAS  Google Scholar 

  99. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol. 1991; 9: 509–524.

    PubMed  CAS  Google Scholar 

  100. Hardman PD, Robb JE, Kerr GR, et al. The value of internal fixation and radiotherapy in the management of upper and lower limb bone metastases. Clin Oncol (R Coll Radiol). 1992; 4: 244–248.

    Article  CAS  Google Scholar 

  101. Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg. 1993; 76: 402–416.

    PubMed  CAS  Google Scholar 

  102. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592–596

    Google Scholar 

  103. Cherny NI, Portnoy RK. The management of cancer pain. CA Cancer J Clin. 1994; 44: 263–303.

    Article  PubMed  CAS  Google Scholar 

  104. Hammack JE, Loprinzi CL. Use of orally administered opioids for cancer-related pain. Mayo Clin Proc. 1994; 69: 384–390.

    Article  PubMed  CAS  Google Scholar 

  105. Eisenberger E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis.J Clin Oncol. 1994;12:2756–2765

    Google Scholar 

  106. Kantor TG. Control of pain by nonsteroidal anti-inflammatory drugs. Med Clin of North America. 1982; 66: 1053–1059.

    CAS  Google Scholar 

  107. Benson RC, Jr., Hasan SM, Jones AG, et al. External beam radiotherapy for palliation of pain from metastatic carcinoma of the prostate. J Urol. 1981; 127: 69–71.

    Google Scholar 

  108. Gilbert HA, Kagan AR, Nussbaum H, et al. Evaluation of radiation therapy for bone metastases: pain relief and quality of life. Am J Roentgenol. 1977; 129: 1095–1096.

    Article  CAS  Google Scholar 

  109. Robinson RG, Preston DF, Spicer JA, et al. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med. 1992; 22: 28–32.

    Article  PubMed  CAS  Google Scholar 

  110. Maxon FR III, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991; 32: 1877–1881.

    PubMed  Google Scholar 

  111. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial J Nucl Med. 1993;34:1839–1844

    Google Scholar 

  112. Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer. 1994;70:554–558

    Google Scholar 

  113. Thurlimann B, Morant R, Jungi WF. Pamidronate (APD) for bone pain: final results of a dose-effect study. Proc ASCO. 1992; 11.

    Google Scholar 

  114. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989;116:67–72

    Google Scholar 

  115. Eisenhut M, Berberich R, Kimmig B, et al. Iodine131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med. 1986; 27: 1255–1261.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. David C. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald L. Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Henry L. Schwartz Department of Geriatrics and Adult Development, The Mount Sinai Medical Center, 10029-6574, New York, NY, USA

    Christine K. Cassel M.D. (Professor and Chairman) & Diane E. Meier M.D. (Associate Professor) (Professor and Chairman) &  (Associate Professor)

  2. Center for Study of Aging and Geriatric Research Education and Clinical Center, Duke University Medical Center, 27710, Durham, NC, USA

    Harvey J. Cohen M.D. (Director) (Director)

  3. University of Washington Medical Center, 98195, Seattle, WA, USA

    Eric B. Larson M.D., M.P.H. (Medical Director) (Medical Director)

  4. Gerontology Division, Harvard Medical School, Brigham and Women’s Hospital, 02115, Boston, MA, USA

    Neil M. Resnick M.D. (Chief) (Chief)

  5. Geriatric Research Education and Clinical Center, Sepulveda VA Medical Center, 91343, Sepulveda, CA, USA

    Laurence Z. Rubenstein M.D., M.P.H. (Director) (Director)

  6. Department of Medicine, University of Chicago, 60637, Chicago, IL, USA

    Leif B. Sorensen M.D. (Professor and Vice Chairman) (Professor and Vice Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Smith, D.C., Trump, D.L. (1997). Prostate Cancer. In: Cassel, C.K., et al. Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-2705-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-2705-0_23

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-2707-4

  • Online ISBN: 978-1-4757-2705-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation